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Figure 4. NAT activity of recombinant hNaa10p WT or p.Ser37Pro 
towards synthetic N-terminal peptides. A) and B) Purified MBP-hNaa10p 
WT or p.Ser37Pro were mixed with the indicated oligopeptide substrates (200 
µM for SESSS and 250 µM for DDDIA) and saturated levels of acetyl-CoA 
(400 µM). Aliquots were collected at indicated time points and the acetylation 
reactions were quantified using reverse phase HPLC peptide separation. 
Error bars indicate the standard deviation based on three independent 
experiments. The five first amino acids in the peptides are indicated, for 
further details see materials and methods. Time dependent acetylation 
reactions were performed to determine initial velocity conditions when 
comparing the WT and Ser37Pro NAT-activities towards different 
oligopeptides. C) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed with 
the indicated oligopeptide substrates (200 µM for SESSS and AVFAD, and 
250 µM for DDDIA and EEEIA) and saturated levels of acetyl-CoA (400 µM) 
and incubated for 15 minutes (DDDIA and EEEIA) or 20 minutes (SESSS and 
AVFAD), at 37°C in acetylation buffer. The acetylation activity was determined 
as above. Error bars indicate the standard deviation based on three 
independent experiments. Black bars indicate the acetylation capacity of the 
MBP-hNaa10p wild type (WT), while white bars indicate the acetylation 
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first amino acids 
in the peptides are indicated. 
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  non-­‐paid	  consul:ng:	  
The	  Big	  Picture	  
•  Over	  the	  course	  of	  my	  en:re	  career,	  I	  want	  to	  
help	  understand	  the	  pathophysiology	  of	  
severe	  disorders	  with	  neuropsychiatric	  
manifesta:ons,	  including	  such	  things	  as	  
developmental	  delay,	  intellectual	  disability,	  
and	  other	  neurobehavioral	  outcomes.	  
•  This	  will	  certainly	  uncover	  new	  biology	  along	  
the	  way.	  
Rare	  Diseases	  
The	  Story	  began	  for	  me	  at	  least	  by	  1993….	  
	  
when	  I	  studied,	  as	  an	  undergraduate	  student,	  the	  
role	  of	  thyroid	  hormone	  in	  cre5nism,	  which	  is	  
caused	  by	  lack	  of	  iodine	  during	  maternal	  
pregnancy,	  so	  this	  is	  an	  environmentally	  triggered	  
disease,	  modiﬁed	  by	  gene5c	  and	  other	  factors.	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1996-­‐97	  
•  In	  Cambridge,	  England	  at	  Christ’s	  College,	  
worked	  with	  Mar:n	  Evans	  on	  mouse	  
knockouts	  and	  models	  of	  human	  disease.	  
•  Met	  Alexander	  Bearn,	  a	  dis:nguished	  human	  
gene:cist	  who	  happened	  to	  be	  a	  fellow	  in	  
residence	  at	  the	  :me.	  He	  wrote	  the	  deﬁni:ve	  
biography	  of	  Archibald	  Garrod.	  
•  At	  that	  :me,	  I	  formalized	  my	  goal	  to	  study	  
human	  gene:cs	  long-­‐term.	  
What	  will	  it	  take	  for	  me	  to	  study	  human	  gene5cs	  
and	  certain	  diseases	  in	  detail	  over	  my	  en5re	  
career?	  
“The	  M.D.	  does	  not	  make	  you	  a	  physician,	  
but	  it	  prepares	  you	  to	  become	  one.	  
	  
The	  Ph.D.	  does	  not	  make	  you	  a	  scien:st,	  
but	  it	  prepares	  you	  to	  become	  one.”	  
	  
-­‐Olaf	  Andersen,	  M.D.	  
Director	  of	  Cornell/Rockefeller/Sloan-­‐KeSering	  	  
M.D./Ph.D.	  program	  
	  
M.D.	  Ph.D.	  training	  1997-­‐2004	  
•  Much	  learning	  of	  human	  physiology,	  anatomy	  
and	  disease	  at	  Weill	  Cornell	  Medical	  College.	  
	  
•  Ph.D.	  in	  bacterial	  gene:cs	  and	  chemical	  
biology	  with	  Tom	  Muir	  at	  Rockefeller	  and	  
Richard	  Novick	  at	  NYU.	  
2004-­‐	  present	  
Becoming	  a	  clinician	  through	  clinical	  residency	  
and	  prac:ce.	  
	  	  
Becoming	  a	  scien:st	  through	  focusing	  on	  the	  
pathophysiology	  of	  idiopathic	  syndromes.	  
	  
2009-­‐	  present	  
Discovering	  a	  new	  syndrome	  and	  its	  
gene:c	  basis.	  
"This	  exempliﬁes	  an	  excep:onally	  
rare	  disease,	  but	  the	  same	  type	  
of	  strategy	  is	  now	  going	  to	  be	  
applied	  to	  more	  common	  
diseases	  to	  get	  the	  root	  cause,"	  
says	  Eric	  Topol,	  a	  medical	  
gene:cist	  at	  the	  Scripps	  Research	  
Ins:tute	  in	  La	  Jolla,	  California.	  
	  
"This	  is	  one	  of	  the	  most	  exci:ng	  
things	  in	  medicine,"	  says	  Topol.	  
"We're	  going	  to	  take	  the	  term	  
'idiopathic'	  which,	  basically	  
means	  'we	  don't'	  know,'	  and	  
eliminate	  it."	  
Ogden	  Syndrome	  
We	  found	  the	  SAME	  muta:on	  in	  two	  unrelated	  families,	  with	  a	  very	  similar	  
phenotype	  in	  both	  families,	  helping	  prove	  that	  this	  genotype	  contributes	  to	  the	  
phenotype	  observed.	  
First	  boy.	  Called	  “a	  liSle	  old	  man”	  by	  
the	  family.	  Died	  around	  ~1	  year	  of	  
age,	  from	  cardiac	  arrhythmias.	  
This	  is	  the	  ﬁrst	  boy	  in	  the	  late	  1970’s.	  
prominence	  of	  eyes,	  down-­‐sloping	  palpebral	  ﬁssures,	  thickened	  
eyelids,	  large	  ears,	  beaking	  of	  nose,	  ﬂared	  nares,	  hypoplas:c	  nasal	  
alae,	  short	  columella,	  protruding	  upper	  lip,	  micro-­‐retrognathia	  
	  
This	  is	  the	  “Proband”	  photograph	  presented	  at	  Case	  Conference.	  
These	  are	  the	  Major	  Features	  of	  the	  Syndrome.	  
!  We	  performed	  X-­‐chromosome	  exon	  capture	  
with	  Agilent,	  followed	  by	  Next	  Gen	  
Sequencing	  with	  Illumina.	  
!  We	  analyzed	  the	  data	  with	  ANNOVAR	  and	  
VAAST	  (Variant	  Annota5on,	  Analysis	  and	  
Search	  Tool).	  New	  computa5onal	  tools	  for	  
iden5fying	  disease-­‐causing	  muta5ons	  by	  
individual	  genome	  sequencing.	  	  
	  
Yandell,	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VAAST	  integrates	  AAS	  &	  Variant	  frequencies	  
in	  a	  single	  probabilis5c	  framework	  	  
 
•   non-coding variants scored using allele frequency differences 
•  ni : frequency of variant type among all variants observed in 
Background and Target genomes 
 
•  ai: frequency of variant type among disease causing mutations in 
OMIM 
•  This approach means that every variant can be scored, non-synonymous,   
  synonymous, coding, and non-coding. Phylogenetic conservation not     
  required. 

Mutation 
WT 
C C C 
Pro37 
Proband  
Unaffected 
Brother 
C T T G G	  T C T C 
Ser37 
C 
T 
This is the mutation we found… one nucleotide change 
out of 6 billion nucleotides in a diploid genome… 
Iden:ty	  by	  Descent	  Analysis	  shows	  
that	  the	  muta:on	  must	  have	  arisen	  
independently	  in	  two	  diﬀerent	  
families.	  
Courtesy	  of	  Chad	  Huﬀ	  and	  Lynn	  Jorde	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“There	  are	  ~12	  billion	  nucleo:des	  in	  every	  cell	  of	  the	  human	  body,	  and	  there	  are	  
~25-­‐100	  trillion	  cells	  in	  each	  human	  body.	  Given	  soma:c	  mosaicism,	  epigene:c	  
changes	  and	  environmental	  diﬀerences,	  no	  two	  human	  beings	  are	  the	  same,	  
par:cularly	  as	  there	  are	  only	  ~7	  billion	  people	  on	  the	  planet”.	  	  
	  
	  To	  appear	  as	  a	  book	  chapter:	  Lyon,	  G.	  J.*	  and	  O'Rawe	  J.A.	  Human	  gene:cs	  and	  clinical	  
aspects	  of	  neurodevelopmental	  disorders.	  In:	  The	  Gene:cs	  of	  Neurodevelopmental	  Disorders,	  
publisher:	  Wiley,	  2014.	  	  
	  
Moved	  to	  CSHL	  in	  2012	  
A	  conceptual	  model	  of	  genotype-­‐phenotype	  correla5ons.	  	  The	  y	  plane	  represents	  a	  
phenotypic	  spectrum,	  the	  x	  plane	  represents	  the	  canalized	  progression	  of	  development	  
through	  :me,	  and	  the	  z	  plane	  represents	  environmental	  ﬂuctua:ons.	  	  	  
Time	  
Environment	  
Phenotypic	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random mutation modeling40 to calculate the likelihood that observed 
(de novo) mutations have a damaging effect. Similar prioritizations 
are provided by tools that score individual mutation severity (SIFT, 
PolyPhen2, MutationTaster, MutPred, CONDEL, etc.), some of which 
can be adapted to a gene-based prioritization score from genome-wide 
data41. These population data provide a powerful unbiased approach 
to home in on genes that are likely to be among the most penetrant 
because of the complete absence of disruptive variation in the general 
population (for example, CHD8 or DYRK1A). A critical aspect of such 
analyses is the reliability of a particular gene model. Most human 
genes show evidence of alternative splice forms, many of which have 
no known function. Apparent hotspots of mutation for a particular 
exon (often exon-intron boundaries) in both cases and controls may 
suggest misannotation, the presence of a processed pseudogene or an 
alternative, nonfunctional splice form.
Pathway enrichment and links to cancer biology
Another popular approach to discern the most important gene 
candidates for further disease association and characterization has 
been to identify specific biological networks of genes enriched in 
cases as compared to controls. Although this approach cannot be used 
unequivocally to define causality, membership of a specific gene in a 
particular protein-protein interaction (PPI) or coexpression network 
may increase the likelihood of its association with disease. Numerous 
studies have reported significant enrichment of both de novo 
CNV and single-nucleotide variant (SNV) mutations in particular 
pathways3,4,42,43. O’Roak et al.3, for example, reported a significant 
enrichment of de novo disruptive autism mutations among proteins 
associated with chromatin remodeling and ?-catenin and WNT 
signaling—a finding that was replicated in a follow-up resequencing 
study of more than 2,400 probands. One recent instance, in which 
membership of a new candidate gene in a PPI network led to the 
discovery of an autism-associated gene, is ADNP. A single ADNP 
LoF mutation was initially observed in exome sequencing studies. 
Although the observed mutation frequency in this gene did not reach 
statistical significance when cases and controls were compared20, 
it was strongly implicated in the PPI network originally defined 
by O’Roak et al.3 Targeted resequencing experiments combined 
with clinical exome sequencing identified several more cases with 
de novo mutations and remarkably similar phenotypes represent-
ing a new SWI-SNF–related autism syndrome (Fig. 3)44. Notably, 
many of the genes implicated in the ?-catenin pathway have also been 
described as mutated in patients with ID1 but not in patients with 
SCZ. Similarly, an enrichment of genes interacting with FMR1 (also 
known as FMRP)—the gene responsible for fragile X syndrome—has 
been reported with de novo mutations in ASD5, epilepsy11 and, most 
recently, SCZ10,45. Whether this observation is due to the relative high 
incidence of cases that also presented with comorbid ID remains to 
be determined.
In addition to PPI networks, studies of coexpression have shown 
enrichment for specific spatio-temporal patterns of expression. 
A study of coexpressed genes affected by de novo mutations reported 
an enrichment in fetal prefrontal cortical network in SCZ8, which is 
in line with the finding by Xu et al.9 that genes with higher expression 
Table 4 Recurrent identical de novo mutations in 6 genes identified in 11 exome studies with different neurodevelopmental phenotypes
Gene Coding effect Mutation (genomic DNA level) Mutation (cDNA level)
Mutation  
(protein level) Study Disorder
ALG13 Missense ChrX(GRCh37):g.110928268A>G NM_001099922.2:c.320A>G p.Asn107Ser de Ligt et al.1 ID
ALG13 Missense ChrX(GRCh37):g.110928268A>G NM_001099922.2:c.320A>G p.Asn107Ser Allen et al.11 EE
ALG13 Missense ChrX(GRCh37):g.110928268A>G NM_001099922.2:c.320A>G p.Asn107Ser Allen et al.11 EE
KCNQ3 Missense Chr8(GRCh37):g.133192493G>A NM_001204824.1:c.328C>T p.Arg110Cys Rauch et al.2 ID
KCNQ3 Missense Chr8(GRCh37):g.133192493G>A NM_001204824.1:c.328C>T p.Arg110Cys Allen et al.11 EE
SCN1A Splice donor LRG_8:g.24003G>A NM_006920.4:c.602+1G>A p.? Allen et al.11 EE
SCN1A Splice donor LRG_8:g.24003G>A NM_006920.4:c.602+1G>A p.? Allen et al.11 EE
CUX2 Missense Chr12(GRCh37):g.111748354G>A NM_015267.3:c.1768G>A p.Glu590Lys Rauch et al.2 ID
CUX2 Missense Chr12(GRCh37):g.111748354G>A NM_015267.3:c.1768G>A p.Glu590Lys Allen et al.11 EE
SCN2A Missense Chr2(GRCh37):g.166198975G>A NM_021007.2:c.2558G>A p.Arg853Gln Allen et al.11 EE
SCN2A Missense Chr2(GRCh37):g.166198975G>A NM_021007.2:c.2558G>A p.Arg853Gln Allen et al.11 EE
DUSP15 Missense Chr20(GRCh37):g.30450489G>A NM_080611.2:c.320C>T p.Thr107Met Neale et al.7 ASD
DUSP15 Missense Chr20(GRCh37):g.30450489G>A NM_080611.2:c.320C>T p.Thr107Met Fromer et al.10 SCZ
EE, epileptic encephalopathies; ASD, autism spectrum disorder; ID, intellectual disability; SCZ, schizophrenia.
Figure 1 Genes with recurrent de novo mutations in four 
neurodevelopmental disorders. (a) We estimate the number of fully penetrant 
genes that can explain disease once mutated, based on a de novo model 
using the ‘unseen species problem’. We consider all recurrent missense or 
LoF de novo mutations pathogenic, as well as a defined fraction of mutations 
in genes observed just once (because it is unlikely that all de novo mutations 
are pathogenic). The ratio between genes mutated recurrently and the rate 
of singleton mutations suggests an estimate for the true number of genes 
pathogenic when mutated. Including more singleton mutations increases 
the fraction of each disorder explained by single de novo SNVs at the cost 
of including more genes as pathogenic. Initial exome sequencing studies of 
epilepsy and ID focused on specific pediatric subtypes or the most severe 
cases; thus, the number of generalized epilepsy- or ID-associated genes is 
likely to be much higher. EE, epileptic encephalopathies; ASD, autism spectrum disorder; ID, intellectual disability; SCZ, schizophrenia. (b) Expected  
hit rate (or sensitivity) of true positive genes discovered using trio sequencing studies (under a family-wise error rate of 5%; that is, each gene passes exome-
wide significance of 2.6 × 10−6). We estimate the power of trio sequencing to detect statistically significant associations for disease-associated genes,  
under the assumption that 10% or 20% of singleton mutations could be fully penetrant (vertical bars in a). We assume the distribution of these genes is 
uniform within each disorder and that they do not differ significantly from all genes in terms of length and mutability, although these are taken into account 
when determining significance.
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Recent exome (and genome) sequencing studies of families have aimed 
to comprehensively discover genetic variation to identify the most 
likely causal mutation in patients with disease. Sequencing studies of 
parent-proband trios for probands with intellectual disability (ID)1,2, 
autism spectrum disorder (ASD)3–7, schizophrenia (SCZ)8–10 and epi-
lepsy11 have all suggested that de novo point mutations are important 
in pediatric and adult disorders of brain development (Table 1). The 
relative contribution of de novo mutations to each disorder remains to 
be determined but appears to correlate well with the degree of reduced 
fitness or fecundity of the given condition12. However, not only 
de novo events but also rare inherited copy number variants (CNVs) 
can have an effect on fecundity, though their overall effect on fecundity 
is still debated13. Biologically, 75–80% of de novo point mutations arise 
paternally3,14, likely as a result of the greater number of cell divisions 
in the male germline lineage than in the female lineage. These findings 
are consistent with some epidemiological data that find advancing 
paternal age to be a significant predictor of ASD, ID and SCZ15–17 and 
argue for the need to properly control for paternal age when comparing 
mutation rates between probands and siblings. The importance of 
de novo and private rare mutations is especially important clinically, 
as there are now reports of diagnostic yields ranging from 10–55%  
for select (usually the most severe) groups of patients with ID1,2 and 
epilepsy18, in addition to resolution of unsolved Mendelian disorders19. 
It is clear that next-generation sequencing approaches have provided 
powerful tools for identifying genes harboring potentially pathogenic 
mutations. Deciding which genes to pursue, however, is not always 
self-evident because follow-up research and diagnostic studies are 
critical to understanding the full contribution of a particular mutation 
to its respective phenotype.
In this Review, we will discuss the prioritization of candidate genes 
identified through sequencing studies, show emerging trends and 
highlight potential strategies for subsequent functional characteriza-
tion of these neurodevelopmental genes. We focus on lessons learned 
from 11 recent studies that report 2,368 de novo mutations from a 
total of 2,358 probands and 600 de novo mutations from 731 controls 
(Table 1). The bulk of the data originate from sequencing studies 
of parents and probands with ASD, ID and epileptic encephalopa-
thies, but more recent studies have also highlighted the importance of 
de novo mutations in SCZ. There is evidence that de novo mutations, 
particularly disruptive mutations, occur in the same genes despite the 
nosological distinction for these different diseases. For the purpose of 
this Review, we collectively term these diseases ‘neurodevelopmental 
disorders’ but recognize that some, especially adult-onset diseases 
such as SCZ, may have etiologic components that are not neurode-
velopmental in origin.
Recurrently mutated genes
One of the frequently used concepts in considering possible ‘new 
disease genes’ responsible for a given neurodevelopmental pheno-
type is the recurrence of de novo mutations in the same gene, along 
with the absence of such mutations in healthy controls. This rule 
follows the precedent established for the discovery of pathogenic 
de novo CNVs during the last decade, with the highest priority 
given to recurrent mutations that lead to a complete loss of func-
tion of one of the parental copies of the gene. Up to ten independ-
ent reports of de novo mutations in SCN2A and nine independent 
reports of de novo mutations in SCN1A and STXBP1 have been 
described (Tables 2 and 3). Strikingly, de novo mutations in those 
genes have so far been found exclusively in probands and never in 
controls. Simulation data suggest that at least two but certainly three 
or more recurrent de novo loss-of-function (LoF) events (that is, 
predicted nonsense, frameshift or canonical splice site mutations) 
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Prioritization of ne rodevelopmental disease 
genes by discovery of new mut tions
Alexande  Hoischen1, Niklas Krumm2 & Evan E Eichler2,3
Advances in genome sequencing technologies have begun to revolutionize neurogenetics, allowing the full spectrum of genetic 
variation to be better understood in relation to disease. Exome sequencing of hundreds to thousands of samples from patients 
with autism spectrum disorder, intellectual disability, epilepsy and schizophrenia provides strong evidence of the importance of 
de novo and gene-disruptive events. There are now several hundred new candidate genes and targeted resequencing technologies 
that allow screening of dozens f genes in tens of thousa ds of individuals with h gh specificity and sensitivity. The de ision 
of which genes to pursue depends on many factors, including recurrence, previous evidence of overlap with pathogenic copy 
number variants, the position of the mutation in the protein, the mutational burden among healthy individuals and membership 
of the candidate gene in disease-implicated protein networks. We discuss these emerging criteria for gene prioritization and the 
potential impact on the field of neuroscience.
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in early fetal life have substantial contribu-
tion to SCZ by de novo mutations. Similarly, 
Willsey et al.46 working with a few high- 
confidence sets of ASD-associated genes as 
seeds reported a convergence of the expres-
sion of these genes in deep-layer cortical 
projection neurons (layers 5 and 6) in mid-
fetal development. Another analysis using a 
larger set of ASD and ID risk genes suggested translational regulation 
by FMR1 and an enrichment in superficial cortical layers43. Implicit 
in these types of analyses is the notion that, while more than 1,000 
genes may be responsible for ASD or ID, in the end the genes will con-
verge on a few highly enriched networks of related genes. It is possible 
that molecular therapies targeted to the network at a specific stage of 
development, as opposed to the individual gene, may be beneficial to 
specific groups of patients.
Related to this, it is intriguing that several recurring genes and 
pathways that have been implicated in neurodevelopmental disease 
have also been associated with different forms of cancer (Fig. 4)47. 
While clear-cut examples such as the mutation of the tumor sup-
pressor genes PTEN (Cowden syndrome) or ARID1B (Coffin-Siris 
syndrome) in neurodevelopmental disease have been extensively 
reviewed48, more recent exome sequencing data from patients with 
neurodevelopmental disease suggest new links. The most striking 
observation here is the identical point mutations reported to cause 
cancer when mutated somatically and severe neurodevelopmental syn-
dromes when mutated in the germline. Examples include the identical 
mutations in SETBP1 (ref. 32), ASXL1 (ref. 49) and EZH2 (ref. 50), as 
well as several genes of the RAS–MAP kinase pathway associated with 
parental-age-effect Mendelian disorders51 (Supplementary Table 1). 
It is important to stress that this is an observation at an individual 
gene level and should not be translated to an epidemiological link: 
that is, this cannot be generalized to speculate that patients with neuro-
developmental disorders in these specific genes will all be at a higher 
risk for certain cancer types. Instead, it is likely that this convergence 
represents a selection of genes that are fundamental to cell biology 
(for example, cell proliferation and/or membership in multi-subunit 
complexes associated with chromatin remodeling). There is also the 
distinct possibility of pleiotropy; that is, the genes and pathways have 
completely unrelated functions, explaining developmental defects and 
cancer independently. Therefore, de novo mutations in those genes 
can result in different outcomes depending on timing, genetic back-
ground and cellular context. Nevertheless, there may be advantages 
to integrating sequence data from patients with neurodevelopmental 
disease and massive sequencing programs devoted to the discovery of 
somatic mutations in tumors—for example, the International Cancer 
Genome Project52. It is possible that these intersections will help to 
further prioritize genes important in both cellular development and 
neurodevelopment.
Phenotypic similarity of recurrent de novo mutations
Although essential, statistical support of recurrent mutations is 
not the sole arbiter in determining pathogenicity of particular 
mutations and genes. In particular, it is important to consider the 
phenotypic presentation and overlap of the individuals with the same 
presumptive underlying genetic lesion. In this regard, we note that 
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Figure 2 CNV and exome intersections define 
candidate genes. (a,b) Deletion (red) and 
duplication (blue) burden for developmental 
delay or ID cases and controls for two genes, 
DYRK1A (a) and MBD5 (b), as compared to 
sporadic LoF mutations on the basis of exome 
sequencing of 209 autism simplex trios. DYRK1A 
is a strong candidate gene for cognitive deficits 
associated with Down syndrome; LoF mutations 
are associated with minibrain phenotype in 
Drosophila65, autism-like behavior in mouse64 
and a deletion syndrome in humans27,63. MBD5 
has been implicated as the causal gene for 
the 2q23.1 deletion syndrome associated with 
epilepsy, autism and ID91,92.
a bFigure 3 Phenotypic similarity of two patients 
with identical PACS1 de novo mutations and two 
patients with similar ADNP mutations. (a) These 
two unrelated patients show identical de novo 
point mutations (c.607C>T; p.Arg203Trp) in 
PACS1 (RefSeq NM_018026.3)53. The striking 
similarity in phenotype includes low anterior 
hairline, highly arched eyebrows, synophrys, 
hypertelorism with downslanted palpebral 
fissures, long eyelashes, a bulbous nasal tip, a 
flat philtrum with a thin upper lip, downturned 
corners of the mouth and low-set ears. Reprinted 
from ref. 53, Copyright (2012), with permission from The American Society of Human Genetics. (b) These two unrelated patients both show LoF mutations 
in ADNP (c.2496_2499delTAAA; p.Asp832Lysfs*80 and c.2157C>G; p.Tyr719*)44 resulting in a new SWI-SNF–related autism syndrome. Patients present 
with clinical similarities, including a prominent forehead, a thin upper lip and a broad nasal bridge. Reprinted from ref. 44.
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between Lys29 and Gln15 of Naa10p and Asp532 and Gln491 of 
Naa15p. Single point mutations in this region did not break up the 
complex and had only modest effects on substrate binding and cataly-
sis (Table 2), probably owing to the extensiveness of the interface. 
A smaller hydrophobic interface is formed between Naa10p His20 
and Naa15p Phe449 and Trp494 and is supplemented with a hydro-
gen bond between Naa10p Gln25 and Naa15p Arg448. This region 
of Naa15p directly stabilizes the position of the Naa10p ?1 helix as 
well as the Naa10p ?1–?2 loop and as a result is crucial for proper 
complex formation. This is evident from the observation that alanine 
point mutations at either Naa15p Arg448 or Naa15p Phe449 were 
able to disrupt NatA complex formation. Several additional scattered 
intermolecular interactions serve to supplement the Naa10p-Naa15p 
interface (Supplementary Fig. 3).
Molecular basis for Naa15p modulation of Naa10p acetylation
To explore the molecular basis for Naa15p modulation of Naa10p 
acetyltransferase activity, we determined the X-ray crystal structure of 
Naa10p of S. pombe in the absence of Naa15p, for comparison with the 
holo-NatA complex (Table 1). We determined the structure of Naa10p 
(residues 1–156) to 2.00-Å resolution, using a combination of single- 
wavelength anomalous diffraction and molecular replacement (model, 
NAA50) to phase data collected on a selenomethionine-derivatized 
Naa10p protein. An alignment of the complexed and uncomplexed 
forms of Naa10p revealed that the ?1–loop–?2 segment assumes 
a substantially different conformation in the presence of Naa15p 
(Fig. 2a). Notably, this conformational change is driven by the move-
ment of several hydrophobic residues in Naa10p ?2 (Leu28, Leu32 
and Ile36), which make intramolecular interactions with residues in 
Naa10p ?1 and ?3 (Ile8, Leu11, Met14, Tyr55 and Tyr57) in apo-
Naa10p but shift to make alternative intermolecular interactions 
with helices of Naa15p in the NatA complex (Figs. 1c and 2b). As 
a result of this interaction, the C-terminal region of the ?1 helix 
undergoes an additional helical turn, which helps to reposition the 
?1–?2 loop. Notably, docking of the apo-Naa10p structure into the 
corresponding binding pocket of Naa15p showed a clash between the 
Naa10p ?1–loop–?2 and Naa15p Arg448 and Naa15p Phe449 of ?25 
(Fig. 2c)—the same interface that we have shown to be necessary for 
proper complex formation (Fig. 1d and Table 2).
As a result of the Naa15p interaction along one side of the Naa10p 
?1–loop–?2 region, residues on the opposite side of this loop region 
appear to adopt a specific conformation that is essential for catalysis 
of traditional substrates (alanine, cysteine, glycine, serine, threonine 
or valine) (Supplementary Videos 2 and 3). Specifically, Naa10p 
residues Leu22 and Tyr26 shift about 5.0 Å from surface-exposed 
positions to buried positions in the active site, and Naa10p Glu24 
moves by about 4.0 Å, substantially altering the landscape of the NatA 
active site (Fig. 2d). All of these residues are well ordered in both 
structures (Supplementary Fig. 4). Our comparison of the com-
plexed and uncomplexed structures suggests that the auxiliary subunit 
induces an allosteric change in the Naa10p active site to an extent that 
is required for the mechanism of catalysis by the NatA complex, and 
Naa10p is likely to represent an active GNAT fold. Consistent with 
this hypothesis, a backbone alignment of key active site elements in 
active Naa10p with the corresponding region in the independently 
active human NAA50 that selects a 1-Met-Leu-2 N-terminal sequence 
shows a high degree of structural conservation (r.m.s. deviation of 
1.52 Å). The corresponding alignment of the complexed and uncom-
plexed forms of Naa10p showed less structural conservation, with an 
r.m.s. deviation of 2.43 Å (Fig. 2e).
Substrate peptide binding and NatA inhibition
To determine the molecular basis for substrate-specific peptide bind-
ing by NatA, and in particular how, unlike most other NATs, it is able 
to accommodate a number of nonmethionine N-terminal substrates, 
we synthesized a bisubstrate conjugate in which CoA is covalently 
linked to a biologically relevant substrate peptide fragment with the 
sequence 1-SASEA-5 (CoA-SASEA). We performed inhibition stud-
ies with CoA-SASEA and with a control compound, acetonyl CoA, 
which is a nonhydrolyzable acetyl CoA analog (Fig. 3a). Half-maxi-
mum inhibitory concentration (IC50) determinations revealed that 
CoA-SASEA had an IC50 of 1.4 ? 1.0 ?M, whereas acetonyl CoA 
had an IC50 of 380 ? 10 ?M (Fig. 3b). To assess the specificity of this 
inhibitor toward NatA, we also calculated IC50 values of CoA-SASEA 
and acetonyl CoA with NAA50, a NAT that requires a substrate 
N-terminal methionine residue. We found that CoA-SASEA has an 
IC50 of 11 ? 2 ?M, whereas acetonyl CoA has an IC50 of 130 ? 12 ?M 
(Fig. 3b). With NAA50, the addition of a SASEA peptide portion 
was able to increase the potency of acetonyl CoA by only about ten-
fold, whereas with NatA this peptide addition exhibited an increase 
in potency of about 300-fold. The greater potency of acetonyl CoA 
with NAA50 over Naa10p can be explained by the stronger binding of 
acetyl CoA to NAA50 (Km = 27 ? 2 ?M) than to Naa10p (Km = 59 ? 
5 ?M). The markedly higher potency of the CoA-SASEA inhibitor 
b N
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Figure 1 Overall structure of the NatA complex bound to acetyl CoA. (a) Naa10p (teal) and Naa15p (brown) subunits, shown in cartoon, bound to 
acetyl CoA (CPK coloring and stick format). Only Naa15p helices that contact Naa10p are labeled. The dashed brown line represents a disordered 
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increased NAA10’s ranking to first overall in just one
family. Furthermore, after combining variants from the
proband in family 1 with the obligate carrier mother in
family 2, VAAST identified NAA10 as the only statistically
significant candidate.
Although we have noted that the affected infants have
an aged appearance, we have not established any direct
link with progeria or other progeroid syndromes. The
autopsies did not reveal any premature arteriosclerosis or
degeneration of vascular smooth muscle cells, as is seen
in Hutchinson-Gilford progeria syndrome (MIM
176670).43,44 Cell lines now being derived from family 1
and possibly future animal models will provide important
insights about the pathophysiology underlying this previ-
ously unrecognized syndrome.
Supplemental Data
Supplemental Data include six figures and two tables and can be
found with this article online at http://www.cell.com/AJHG/.
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Figure 4. NAT Activity of Recombinant hNaa10p WT
or p.Ser37Pro toward Synthetic N-Terminal Peptides
(A and B) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed
with the indicated oligopeptide substrates (200 mM for SESSS and
250 mM for DDDIA) and saturated levels of acetyl-CoA (400 mM).
Aliquots were collected at indicated time points and the acetyla-
tion reactions were quantified with reverse phase HPLC peptide
separation. Error bars indicate the standard deviation based on
three independent experiments. The five first amino acids in the
peptides are indicated, for further details see Subjects and
Methods. Time-dependent acetylation reactions were performed
to determine initial velocity conditions when comparing the WT
and Ser37Pro NAT activities toward different oligopeptides.
(C) Purified MBP-hNaa10p WTor p.Ser37Pro were mixed with the
indicated oligopeptide substrates (200 mM for SESSS and AVFAD
and 250 mM for DDDIA and EEEIA) and saturated levels of
acetyl-CoA (400 mM) and incubated for 15 min (DDDIA and
EEEIA) or 20 min (SESSS and AVFAD) at 37!C in acetylation buffer.
The acetylation activity was determined as above. Error bars
indicate the standard deviation based on three independent exper-
iments. Black bars indicate the acetylation capacity of the
MBP-hNaa10p WT, whereas white bars indicate the acetylation
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first
amino acids in the peptides are indicated.
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  ﬁbroblasts	  and	  siNatA	  
HeLa	  cells.	  
	  	  
Summary	  
•  Found	  ﬁrst	  human	  gene:c	  disease	  with	  proof	  
involving	  Nt-­‐acetyla:on	  of	  proteins.	  
•  Characterizing	  the	  Nt-­‐acetyla:on	  pathway	  both	  in	  
vitro	  and	  in	  vivo	  to	  reveal	  fundamental	  new	  
biology,	  including	  possible	  drug	  targets.	  
•  Iden:fying	  interac:ng	  components	  and	  more	  
downstream	  substrates	  of	  NatA	  complex.	  
The	  End	  
